東北證券:首予同花順“買入”評級 人工智能或成遠期增長點
格隆匯12月16日丨東北證券發佈同花順的研報指出,人工智能明星產品亮相央視,打造長期增長點。2019年12月8日同花順i問財產品亮相央視併成功回答多個問題,產品知名度大幅提升。公司已推出預警通 APP、AI 理財師 APP、小象來電助理、口袋掃描儀、在線客服、智能外呼、智能質檢等多款產品,能為銀行、保險、證券、基金提供多種解決方案,2019年3月公司備案旗下第一隻私募基金“同花順阿爾法一號”,試水智能量化基金,人工智能或成遠期增長點。預計2019-2021年歸母淨利潤分別為 9.48/12.35/14.46 億,目標價135.42-151.79元,首次覆蓋給予“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.